Edwards(EW) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported total sales of $1.57 billion for Q4 2025, reflecting an 11.6% year-over-year growth, and a full-year growth of 10.7% [4][19] - Adjusted earnings per share (EPS) for Q4 was $0.58, while GAAP EPS was $0.11, impacted by one-time charges related to the GeneValve acquisition and litigation expenses [19][20] - The adjusted gross profit margin for Q4 was 78.3%, slightly down from 79.0% in the previous year, attributed to increased manufacturing expenses [20][21] Business Line Data and Key Metrics Changes - TAVR global sales reached $1.16 billion in Q4, growing 10.6% year-over-year, with procedural growth in the high single digits [9][10] - TMTT sales grew over 40% to $156 million in Q4, with full-year sales exceeding $1 billion [15] - Surgical product group sales were $254 million in Q4, a 2% increase year-over-year, with full-year sales surpassing $1 billion [17] Market Data and Key Metrics Changes - The U.S. market showed strong procedural growth for TAVR, driven by increased urgency in treating severe aortic stenosis patients [11][52] - In Europe, updated guidelines are reshaping clinical discussions and expanding the patient population eligible for TAVR [12][50] - The company noted modest year-over-year share improvement in several key countries, strengthening its leadership position [13] Company Strategy and Development Direction - The company is focused on structural heart solutions, aiming for 8%-10% sales growth in 2026 and a long-term average annual sales growth of 10% [6][9] - Plans include pioneering new therapies, launching next-generation technologies, and expanding indications to treat more patients [8][9] - The company is investing in patient access initiatives and partnerships, such as with the American Heart Association, to improve care for heart valve disease [12][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting 2026 sales and EPS guidance, citing strong Q4 performance and growth catalysts [25][26] - The company anticipates a potential tailwind from an updated national coverage determination for TAVR later in the year [7][36] - Management highlighted the importance of lifetime management in TAVR, emphasizing the shift towards earlier treatment of aortic stenosis [41][42] Other Important Information - The company maintains a strong balance sheet with approximately $3 billion in cash and cash equivalents [23] - There is approximately $2 billion remaining under the share repurchase authorization, with plans to continue repurchasing shares opportunistically [24][47] Q&A Session Summary Question: Insights on TAVR growth and market share - Management noted strong TAVR growth of 10.6% year-over-year, driven by compelling clinical evidence and a renewed focus on TAVR as a treatment option [28] Question: Increased spending on market access initiatives - The company increased SG&A spending by $112 million year-over-year to support strategic investments in patient access and education [30] Question: Impact of distributor inventory adjustments - The company clarified that the distributor adjustments in Q4 were specific to one country and did not significantly impact overall sales [55]